Wealthfront Advisers
NTLA icon

Wealthfront Advisers’s Intellia Therapeutics NTLA Stock Holding History

Wealthfront Advisers’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$308K Buy
18,196
+3,746
+26% +$52.4K ﹤0.01% 981
2026
Q1 		$185K Buy
14,450
+1,018
+8% +$13K ﹤0.01% 1032
2025
Q4 		$121K Buy
+13,432
New +$185K ﹤0.01% 1028

Other funds holding NTLA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $2.17B AUM 134.87% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Wealthfront Advisers's NTLA Position: Q2 2026 in Review

Wealthfront Advisers increased its Intellia Therapeutics (NTLA) stake by 26% in Q2 2026, buying an estimated $52.4K and bringing the position to 18,196 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #981.

Wealthfront Advisers first reported a position in NTLA in Q4 2025 and has held it in 3 quarters since. 190 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Wealthfront Advisers held 18,196 shares of Intellia Therapeutics worth $308K as of Q2 2026.
  • Wealthfront Advisers bought 3,746 Intellia Therapeutics shares in Q2 2026, an estimated $52.4K.
  • Intellia Therapeutics made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #981 holding.
  • Wealthfront Advisers first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 190 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.